PMID- 30601153
OWN - NLM
STAT- Publisher
LR  - 20190118
IS  - 1473-5571 (Electronic)
IS  - 0269-9370 (Linking)
DP  - 2018 Dec 19
TI  - Associations between baseline biomarkers and lung function in HIV-positive
      individuals.
LID - 10.1097/QAD.0000000000002101 [doi]
AB  - OBJECTIVE: To analyze the association of baseline biomarker data with cross
      sectional lung function and subsequent decline in lung function in HIV-positive
      persons. DESIGN: Lung function was modeled in all START pulmonary substudy
      participants who had baseline biomarker data and good-quality spirometry. In
      longitudinal analyses we restricted to those participants with at least one
      good-quality follow up spirometry test. METHODS: We performed linear regression
      of baseline FEV1, FVC, and FEV1/FVC and their longitudinal slopes on
      log2-transformed baseline biomarkers with adjustment for age, sex, race, region, 
      smoking status, baseline CD4+ T-cell counts, and baseline HIV-RNA. Biomarkers
      included D-dimer, hsCRP, IL-6, IL-27, serum amyloid A, sICAM-1, sVCAM-1, albumin,
      and total bilirubin. RESULTS: Among 903 included participants, baseline median
      age was 36 years, CD4 count was 647 cells/mm, and 28.5% were current smokers. In 
      adjusted analyses, elevated markers of systemic inflammation (hsCRP, IL-6, and
      serum amyloid A) were associated with lower baseline FEV1 and FVC. Elevated
      D-dimer and IL-6 were associated with worse airflow obstruction (lower FEV1/FVC).
      Despite these cross-sectional associations at baseline, no associations were
      found between baseline biomarkers and subsequent longitudinal lung function
      decline over a median follow-up time of 3.9 years (3,293 spirometry-years of
      follow up). CONCLUSIONS: Commonly available biomarkers, in particular markers of 
      systemic inflammation, are associated with worse cross-sectional lung function,
      but do not associate with subsequent lung function decline among HIV-positive
      persons with early HIV infection and baseline CD4+ T-cell counts >500 cells/mm.
FAU - Macdonald, David M
AU  - Macdonald DM
AD  - Minneapolis VA Health Care System, Minneapolis/USA.
AD  - University of Minnesota, Minneapolis/USA.
AD  - D.M. MacDonald and A.D. Zanotto shared co-primary author responsibilities.
FAU - Zanotto, Alexander D
AU  - Zanotto AD
AD  - Minneapolis VA Health Care System, Minneapolis/USA.
AD  - University of Minnesota, Minneapolis/USA.
AD  - D.M. MacDonald and A.D. Zanotto shared co-primary author responsibilities.
FAU - Collins, Gary
AU  - Collins G
AD  - University of Minnesota, Minneapolis/USA.
FAU - Baker, Jason V
AU  - Baker JV
AD  - Hennepin Country Medical Center, Minneapolis/USA.
FAU - Czarnecki, Marcin
AU  - Czarnecki M
AD  - Institution of EMC Instytut Medyczny SA, Wroclaw/Poland.
FAU - Loiza, Eliana
AU  - Loiza E
AD  - IDEAA Foundation, Buenos Aires/Argentina.
FAU - Nixon, Daniel E
AU  - Nixon DE
AD  - Virginia Commonwealth University, Richmond/USA.
FAU - Papastamopoulos, Vasileios
AU  - Papastamopoulos V
AD  - Evangelismos General Hospital, Athens/Greece.
FAU - Wendt, Chris H
AU  - Wendt CH
AD  - Minneapolis VA Health Care System, Minneapolis/USA.
AD  - University of Minnesota, Minneapolis/USA.
FAU - Wood, Robin
AU  - Wood R
AD  - Desmond Tutu HIV Foundation, Cape Town/South Africa.
FAU - Kunisaki, Ken M
AU  - Kunisaki KM
AD  - Minneapolis VA Health Care System, Minneapolis/USA.
AD  - University of Minnesota, Minneapolis/USA.
CN  - INSIGHT START Pulmonary Substudy Group
LA  - eng
GR  - R01 HL096453/HL/NHLBI NIH HHS/United States
GR  - UM1 AI068641/AI/NIAID NIH HHS/United States
GR  - UM1 AI120197/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20181219
PL  - England
TA  - AIDS
JT  - AIDS (London, England)
JID - 8710219
EDAT- 2019/01/03 06:00
MHDA- 2019/01/03 06:00
CRDT- 2019/01/03 06:00
PHST- 2019/01/03 06:00 [entrez]
PHST- 2019/01/03 06:00 [pubmed]
PHST- 2019/01/03 06:00 [medline]
AID - 10.1097/QAD.0000000000002101 [doi]
PST - aheadofprint
SO  - AIDS. 2018 Dec 19. doi: 10.1097/QAD.0000000000002101.

PMID- 30600702
OWN - NLM
STAT- Publisher
LR  - 20190102
IS  - 1931-8405 (Electronic)
IS  - 0889-2229 (Linking)
DP  - 2019 Jan 2
TI  - Therapeutic immunisation benefits mucosal-associated invariant T-cell recovery in
      contrast to IL-2, GM-CSF, and rhGH addition in HIV-1+ treated patients:
      individual case reports from phase I trial.
LID - 10.1089/AID.2018.0176 [doi]
AB  - MAIT cell populations are reduced in frequency in HIV-1+ patients, and this
      disruption is associated with systemic immune activation. Reconstitution of MAIT 
      frequency may benefit HIV-1 infected individuals, however only recently has in
      vivo work been endeavoured. Treatment with IL-2, GM-CSF and rhGH immunotherapy
      combined with an HIV-1 vaccine in the context of ART has shown to reconstitute
      CD4 T-cell population numbers and function. In this study cryopreserved
      peripheral blood mononuclear cells (PBMC) from 12 HIV-1+ patients who were
      undergoing a combination of HIV-1 vaccine and/or IL-2, GM-CSF and rhGH
      immunotherapy in conjunction with ART were analysed to assess the potential of
      this treatment to promote MAIT cell proliferation. PBMC were thawed from study
      baseline, week 2 and week 48 time-points, fluorescently stained for MAIT cell
      markers and assessed by flow cytometric analysis. Matched pairs and inter-group
      results were statistically compared using appropriate methods. MAIT cell
      frequency was increased from baseline at 48 weeks in participants who received
      vaccine only, whereas individuals receiving IL-2, GM-CSF and rhGH immunotherapy
      with or without vaccine did not show additional benefit. Whilst IL-2, GM-CSF and 
      rhGH treatment promotes CD4 T-cell reconstitution and HIV-1-specific T-cell
      function, it does not support MAIT cell recovery in patients on suppressive ART. 
      Therapeutic immunisation however has a positive effect, highlighting the
      importance of aiming for balanced promotion of T-cell population reconstitution
      to impact on HIV-1 transmission and pathogenesis.
FAU - Cocker, Alexander T H
AU  - Cocker ATH
AD  - Imperial College London, Department of Medicine , Centre for Immunology and
      Vaccinology , Chelsea and Westminster Hospital , 369 Fulham Road , London, United
      Kingdom of Great Britain and Northern Ireland , SW10 9NH ;
      a.cocker15@imperial.ac.uk.
FAU - Greathead, Louise
AU  - Greathead L
AD  - Imperial College London, Department of Medicine, London, United Kingdom of Great 
      Britain and Northern Ireland ; louise.greathead@nhs.net.
FAU - Herasimtschuk, Anna A
AU  - Herasimtschuk AA
AD  - Imperial College London, Department of Medicine, London, United Kingdom of Great 
      Britain and Northern Ireland ; annaherasimtschuk@gmail.com.
FAU - Mandalia, Sundhiya
AU  - Mandalia S
AD  - Imperial College London, Department of Medicine , Chelsea and Westminster
      Hospital , 369 Fulham Road , London , London, United Kingdom of Great Britain and
      Northern Ireland , SW10 9NH ; s.mandalia@imperial.ac.uk.
FAU - Kelleher, Peter
AU  - Kelleher P
AD  - Imperial College London, Department of Medicine, London, United Kingdom of Great 
      Britain and Northern Ireland ; p.kelleher@imperial.ac.uk.
FAU - Imami, Nesrina
AU  - Imami N
AD  - Imperial College London, Department of Medicine, London, United Kingdom of Great 
      Britain and Northern Ireland ; n.imami@imperial.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20190102
PL  - United States
TA  - AIDS Res Hum Retroviruses
JT  - AIDS research and human retroviruses
JID - 8709376
EDAT- 2019/01/03 06:00
MHDA- 2019/01/03 06:00
CRDT- 2019/01/03 06:00
PHST- 2019/01/03 06:00 [entrez]
PHST- 2019/01/03 06:00 [pubmed]
PHST- 2019/01/03 06:00 [medline]
AID - 10.1089/AID.2018.0176 [doi]
PST - aheadofprint
SO  - AIDS Res Hum Retroviruses. 2019 Jan 2. doi: 10.1089/AID.2018.0176.

PMID- 30600686
OWN - NLM
STAT- Publisher
LR  - 20190102
IS  - 1931-8405 (Electronic)
IS  - 0889-2229 (Linking)
DP  - 2019 Jan 2
TI  - Mucosal susceptibility to HIV infection in the proliferative and secretory phases
      of the menstrual cycle.
LID - 10.1089/AID.2018.0154 [doi]
AB  - Factors underlying HIV acquisition in women remain incompletely understood. This 
      study evaluated ex vivo mucosal HIV-1BaL infection (ectocervix, endocervix), T
      cell frequencies and phenotype (ectocervix, endocervix, peripheral blood) and
      HIV-1BaL-induced tissue immune responses (ectocervix) in the proliferative and
      secretory phases of the menstrual cycle using samples obtained from women
      undergoing hysterectomies. Tissue infectivity (number of productively infected
      explants) and infection level following 500 and/or 50 TCID50 HIV-1BaL challenge
      were similar in the proliferative and secretory phases. Although not associated
      with infection outcomes, higher frequencies of HIV target CD4+47+ T cells and
      stronger HIV-1BaL-induced pro-inflammatory responses were detected in ectocervix 
      in secretory vs. proliferative phase. Independently of the cycle phase, serum E2 
      concentrations were inversely associated with ectocervical and endocervical
      tissue infection levels following high dose 500 TCID50 HIV-1BaL challenge, with
      frequencies of CD4+47+ T cells in endocervix, and with HIV-induced IL2R and IL4
      in ectocervix. Although serum P4 concentrations and P4/E2 ratios were neither
      associated with tissue infection level nor infectivity, high P4 concentrations
      and/or P4/E2 ratios correlated with high frequencies of CD4+47+ T cells in
      ectocervix, low frequencies of CD4+CD103+ blood T cells, low CD4+LFA-1+ T cells
      in endocervix, and pro-inflammatory (IL1, IL17, TNF) ectocervical tissue
      responses to HIV-1BaL. The data suggest an inhibitory effect of E2 on mucosal HIV
      infection, provide insights into potential mechanisms of E2-mediated anti-HIV
      activity, and highlight P4-associated immune changes in the mucosa.
FAU - Calenda, Giulia
AU  - Calenda G
AD  - Population Council, CBR, New York, New York, United States ;
      gcalenda@popcouncil.org.
FAU - Villegas, Guillermo
AU  - Villegas G
AD  - Population Council, CBR, New York, New York, United States ;
      gvillegas@popcouncil.org.
FAU - Reis, Alexandra
AU  - Reis A
AD  - Icahn School of Medicine at Mount Sinai, Obstetrics and Gynecology, New York,
      United States ; alexandra.e.reis@gmail.com.
FAU - Millen, Lily
AU  - Millen L
AD  - Icahn School of Medicine at Mount Sinai, Obstetrics and Gynecology, New York,
      United States ; lpos119@gmail.com.
FAU - Barnable, Patrick James
AU  - Barnable PJ
AD  - Population Council, CBR, New York, New York, United States ;
      pbarnable@popcouncil.org.
FAU - Mamkina, Lisa
AU  - Mamkina L
AD  - Population Council, CBR, New York, New York, United States ; lmamkina@yahoo.com.
FAU - Kumar, Narender
AU  - Kumar N
AD  - Population Council, CBR, New York, New York, United States ;
      nkumar@popcouncil.org.
FAU - Roberts, Kevin
AU  - Roberts K
AD  - Population Council, CBR, New York, New York, United States ;
      kroberts@popcouncil.org.
FAU - Kalir, Tamara
AU  - Kalir T
AD  - Icahn School of Medicine at Mount Sinai, Pathology, New York, United States ;
      Tamara.Kalir@mountsinai.org.
FAU - Martinelli, Elena
AU  - Martinelli E
AD  - Population Council, CBR, New York, New York, United States ;
      emartinelli@popcouncil.org.
FAU - Sperling, Rhoda
AU  - Sperling R
AD  - Icahn School of Medicine at Mount Sinai, Obstetrics and Gynecology, New York,
      United States ; Rhoda.Sperling@mssm.edu.
FAU - Teleshova, Natalia
AU  - Teleshova N
AD  - Population Council, CBR, New York, New York, United States ;
      nteleshova@popcouncil.org.
LA  - eng
PT  - Journal Article
DEP - 20190102
PL  - United States
TA  - AIDS Res Hum Retroviruses
JT  - AIDS research and human retroviruses
JID - 8709376
EDAT- 2019/01/03 06:00
MHDA- 2019/01/03 06:00
CRDT- 2019/01/03 06:00
PHST- 2019/01/03 06:00 [entrez]
PHST- 2019/01/03 06:00 [pubmed]
PHST- 2019/01/03 06:00 [medline]
AID - 10.1089/AID.2018.0154 [doi]
PST - aheadofprint
SO  - AIDS Res Hum Retroviruses. 2019 Jan 2. doi: 10.1089/AID.2018.0154.

PMID- 30602038
OWN - NLM
STAT- Publisher
LR  - 20190102
IS  - 1537-6591 (Electronic)
IS  - 1058-4838 (Linking)
DP  - 2019 Jan 2
TI  - Residual or recurrent precancerous lesions after treatment of cervical lesions in
      HIV-infected women: a systematic review and meta-analysis of treatment failure.
LID - 10.1093/cid/ciy1123 [doi]
AB  - Background: Screening and treating premalignant cervical lesions (CIN2+) is an
      effective way to prevent cervical cancer, and recommendations exist for
      monitoring of treatment success. Yet, there is no specific recommendation for
      HIV-infected women, who are at known increased risk of cervical cancer. Methods: 
      A systematic review was performed by searching MEDLINE, EMBASE and Web of Science
      from January 1980 through May 2018. Eligible studies described prevalence of
      histologically and/or cytologically-defined lesions in HIV-infected women, at
      least 6 months post-treatment. Primary endpoint was treatment failure, defined as
      the presence of residual and/or recurrent high-grade CIN2+/HSIL+ lesions
      post-treatment. Pooled prevalence in HIV-infected women, and odds ratios (OR) for
      HIV-infected compared to HIV-uninfected women were estimated using random-effects
      models. Results: Among 40 eligible studies, pooled prevalence of treatment
      failure in HIV-infected women was 21.4% (95%CI 15.8-27.0). There was no
      significant difference in treatment failure for cryotherapy (13.9%, 95%CI
      6.1-21.6) versus LEEP (13.8%, 95%CI 8.9-18.7,p=0.9), but it was significantly
      higher in women with positive (47.2%, 95%CI 22.0-74.0) than with negative (19.4%,
      95%CI 11.8-30.2) margins (OR 3.4, 95%CI 1.5-7.7). Treatment failure was
      significantly increased in HIV-infected versus HIV-uninfected women, both overall
      (OR 2.7, 95%CI 2.0-3.5) and in all sub-group analyses. Conclusion: There is
      strong evidence for increased risk of treatment failure in HIV-infected women in 
      comparison to their HIV-negative counterparts. The only significant predictor of 
      treatment failure in HIV-infected women was positive margin status, but further
      data is needed on long-term outcomes after ablative treatment in HIV-infected
      women.
FAU - Debeaudrap, Pierre
AU  - Debeaudrap P
AD  - CEPED, Institut de Recherche pour le Developpement, Universite Paris Descartes,
      Paris, France.
FAU - Sobngwi, Joelle
AU  - Sobngwi J
AD  - Recherche - Sante & Developpement, Yaounde, Cameroon.
FAU - Tebeu, Pierre-Marie
AU  - Tebeu PM
AD  - Department of Gynecology, CHU of Yaounde, Yaounde, Cameroon.
AD  - Faculty of Medicine and Biomedical Sciences, University of Yaounde, Cameroon.
AD  - Interstates School of Public Heath in Central Africa, Congo, Brazzaville.
FAU - Clifford, Gary M
AU  - Clifford GM
AD  - International Agency for Research on Cancer, Lyon, France.
LA  - eng
PT  - Journal Article
DEP - 20190102
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases
      Society of America
JID - 9203213
EDAT- 2019/01/03 06:00
MHDA- 2019/01/03 06:00
CRDT- 2019/01/03 06:00
PHST- 2018/07/30 00:00 [received]
PHST- 2019/01/03 06:00 [entrez]
PHST- 2019/01/03 06:00 [pubmed]
PHST- 2019/01/03 06:00 [medline]
AID - 5269500 [pii]
AID - 10.1093/cid/ciy1123 [doi]
PST - aheadofprint
SO  - Clin Infect Dis. 2019 Jan 2. pii: 5269500. doi: 10.1093/cid/ciy1123.

PMID- 30601976
OWN - NLM
STAT- Publisher
LR  - 20190102
IS  - 1537-6591 (Electronic)
IS  - 1058-4838 (Linking)
DP  - 2019 Jan 2
TI  - Dolutegravir monotherapy versus dolutegravir/abacavir/lamivudine for
      virologically suppressed people living with chronic HIV infection: the randomized
      non-inferiority MONCAY trial.
LID - 10.1093/cid/ciy1132 [doi]
AB  - BACKGROUND: We investigated whether dolutegravir monotherapy was able to maintain
      virological suppression in people living with HIV on a successful
      dolutegravir-based triple-therapy. METHODS: MONCAY was a 48-week multicentric,
      randomized, open-label, 12% non-inferiority margin trial. Patients with CD4
      nadir>100/muL, plasma HIV-1 RNA <50 copies/mL for >/=12 months and stable regimen
      with dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) were 1:1 randomized to
      continue their regimen or to DTG monotherapy. The primary endpoint was the
      proportion of patients with HIV RNA <50 copies/mL at week (W) 24 in
      intention-to-treat (ITT) snapshot analysis. Virologic failure (VF) was defined as
      two consecutive HIV-RNA >50 copies/mL within 2 weeks apart. RESULTS:
      Seventy-eight patients were assigned to DTG monotherapy and 80 to continue
      DTG/ABC/3TC. By W24, two patients in DTG group experienced VF without resistance 
      to the INSTI class; one patient discontinued DTG/ABC/3TC due to adverse event.
      The success rate at W24 was 73/78 (93.6%) in the DTG arm and 77/80 (96.3%) in the
      DTG/ABC/3TC arm; difference 2.7%, 95% CI: -5.0 to 10.8. During subsequent
      follow-up, five additional VF occurred in the DTG arm (two of which harbored
      emerging resistance mutation to INSTI). The cumulative incidence of VF at W48 was
      9.7% (95% CI: 2.8 to 16.6) in the DTG arm compared with 0% in the DTG/ABC/3TC arm
      (p=0.005, by the log-rank test). The DSMB recommended to re-intensify the DTG arm
      with standardized triple-therapy. CONCLUSIONS: Because the risk of virological
      failure with resistance increases overtime, we recommend avoiding dolutegravir
      monotherapy as a maintenance strategy among people living with chronic HIV
      infection.
FAU - Hocqueloux, Laurent
AU  - Hocqueloux L
AD  - Service des Maladies Infectieuses et Tropicales, CHR d'Orleans - La Source,
      Orleans, France.
FAU - Raffi, Francois
AU  - Raffi F
AD  - Service des Maladies Infectieuses, CHU Hotel Dieu and INSERM UIC 1413 Nantes
      University, Nantes, France.
FAU - Prazuck, Thierry
AU  - Prazuck T
AD  - Service des Maladies Infectieuses et Tropicales, CHR d'Orleans - La Source,
      Orleans, France.
FAU - Bernard, Louis
AU  - Bernard L
AD  - Service des Maladies Infectieuses, CHU Bretonneau, Tours, France.
FAU - Sunder, Simon
AU  - Sunder S
AD  - Service des Maladies Infectieuses et Tropicales, CHG de Niort, Niort, France.
FAU - Esnault, Jean-Luc
AU  - Esnault JL
AD  - Service des Maladies Infectieuses, CHD de Vendee, La Roche-sur-Yon, France.
FAU - Rey, David
AU  - Rey D
AD  - Le Trait d'Union, Hopitaux Universitaires de Strasbourg, Strasbourg, France.
FAU - Le Moal, Gwenael
AU  - Le Moal G
AD  - Service des Maladies Infectieuses, CHU La Miletrie, Poitiers, France.
FAU - Roncato-Saberan, Mariam
AU  - Roncato-Saberan M
AD  - Service des Maladies Infectieuses, Groupe Hospitalier de La Rochelle - Re -
      Aunis, La Rochelle, France.
FAU - Andre, Marie
AU  - Andre M
AD  - Service des Maladies Infectieuses, CHRU-Brabois, Nancy, France.
FAU - Billaud, Eric
AU  - Billaud E
AD  - Service des Maladies Infectieuses, CHU Hotel Dieu and INSERM UIC 1413 Nantes
      University, Nantes, France.
FAU - Valery, Antoine
AU  - Valery A
AD  - Departement d'Informatique Medicale, CHR d'Orleans - La Source, Orleans, France.
FAU - Avettand-Fenoel, Veronique
AU  - Avettand-Fenoel V
AD  - Laboratoire de Microbiologie clinique, CHU Necker and Universite Paris Descartes,
      Sorbonne Paris Cite, Paris, France.
FAU - Parienti, Jean-Jacques
AU  - Parienti JJ
AD  - Unite de Biostatistique et de Recherche Clinique, CHU de Caen; EA2656 Groupe de
      Recherche sur l'Adaptation Microbienne (GRAM 2.0), Universite Caen Normandie,
      Caen, France.
FAU - Allavena, Clotilde
AU  - Allavena C
AD  - Service des Maladies Infectieuses, CHU Hotel Dieu and INSERM UIC 1413 Nantes
      University, Nantes, France.
CN  - MONCAY study group
LA  - eng
PT  - Journal Article
DEP - 20190102
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases
      Society of America
JID - 9203213
EDAT- 2019/01/03 06:00
MHDA- 2019/01/03 06:00
CRDT- 2019/01/03 06:00
PHST- 2018/10/01 00:00 [received]
PHST- 2019/01/03 06:00 [entrez]
PHST- 2019/01/03 06:00 [pubmed]
PHST- 2019/01/03 06:00 [medline]
AID - 5269432 [pii]
AID - 10.1093/cid/ciy1132 [doi]
PST - aheadofprint
SO  - Clin Infect Dis. 2019 Jan 2. pii: 5269432. doi: 10.1093/cid/ciy1132.

PMID- 30601950
OWN - NLM
STAT- Publisher
LR  - 20190102
IS  - 1537-6591 (Electronic)
IS  - 1058-4838 (Linking)
DP  - 2019 Jan 2
TI  - Non-inferiority of simplified dolutegravir monotherapy compared to continued
      combination antiretroviral therapy that was initiated during primary HIV
      infection: a randomized, controlled, multi-site, open-label, non-inferiority
      trial.
LID - 10.1093/cid/ciy1131 [doi]
AB  - Background: Patients who start combination antiretroviral therapy (cART) during
      primary HIV-1 infection show a smaller HIV-1 latent reservoir, less immune
      activation and a smaller viral diversity compared to patients who start cART
      during chronic infection. We conducted a pilot study to test whether these
      properties would allow sustained virological suppression after simplification of 
      cART to dolutegravir monotherapy. Methods: EARLY-SIMPLIFIED is a randomized, open
      label, non-inferiority trial. Patients who started cART <180 days after estimated
      date of a documented primary HIV-1 infection and had a HIV-1 RNA <50 copies/mL
      plasma for at least 48 weeks were randomized (2:1) to monotherapy with
      dolutegravir 50 mg once-daily or to continuation of cART. The primary efficacy
      endpoint was the proportion of patients with <50 HIV-1 RNA copies/mL on or before
      week 48; non-inferiority margin 10%. Results: Of the 101 patients randomized, 68 
      were assigned to simplification to dolutegravir monotherapy and 33 to
      continuation of cART. At week 48 in the per-protocol population, 67/67 (100%) had
      virological response in the dolutegravir monotherapy group versus 32/32 (100%) in
      the cART group (difference 0.00%, 95%-CI [-100%, 4.76%]). This showed
      non-inferiority of the dolutegravir monotherapy at the pre-specified level.
      Conclusion: In this pilot study consisting of patients who initiated cART <180
      days after the estimated day of a documented primary HIV-1 infection and had <50 
      HIV-1 RNA copies/mL for at least 48 weeks, monotherapy with once-daily
      dolutegravir was non-inferior to cART. Our results suggest that future
      simplification studies should use a stratification according to time of HIV
      infection and start of first cART.
FAU - Braun, Dominique L
AU  - Braun DL
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital
      Zurich, Zurich, Switzerland.
AD  - Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
FAU - Turk, Teja
AU  - Turk T
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital
      Zurich, Zurich, Switzerland.
AD  - Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
FAU - Tschumi, Fabian
AU  - Tschumi F
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital
      Zurich, Zurich, Switzerland.
AD  - Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
FAU - Grube, Christina
AU  - Grube C
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital
      Zurich, Zurich, Switzerland.
FAU - Hampel, Benjamin
AU  - Hampel B
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital
      Zurich, Zurich, Switzerland.
AD  - Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
FAU - Depmeier, Carsten
AU  - Depmeier C
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital
      Zurich, Zurich, Switzerland.
FAU - Schreiber, Peter W
AU  - Schreiber PW
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital
      Zurich, Zurich, Switzerland.
FAU - Brugger, Silvio D
AU  - Brugger SD
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital
      Zurich, Zurich, Switzerland.
FAU - Greiner, Michael
AU  - Greiner M
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital
      Zurich, Zurich, Switzerland.
FAU - Steffens, Daniela
AU  - Steffens D
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital
      Zurich, Zurich, Switzerland.
FAU - de Torrente-Bayard, Cornelia
AU  - de Torrente-Bayard C
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital
      Zurich, Zurich, Switzerland.
FAU - Courlet, Perrine
AU  - Courlet P
AD  - Service of Clinical Pharmacology, University Hospital Center, University of
      Lausanne, Lausanne, Switzerland.
FAU - Neumann, Kathrin
AU  - Neumann K
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital
      Zurich, Zurich, Switzerland.
AD  - Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
FAU - Kuster, Herbert
AU  - Kuster H
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital
      Zurich, Zurich, Switzerland.
FAU - Flepp, Markus
AU  - Flepp M
AD  - Center of Infectious Diseases Zurich, Zurich, Switzerland.
FAU - Bertisch, Barbara
AU  - Bertisch B
AD  - Checkpoint Zurich, Zurich, Switzerland.
AD  - Institute of Global Health, University of Geneva, Switzerland.
FAU - Decosterd, Laurent
AU  - Decosterd L
AD  - Service of Clinical Pharmacology, University Hospital Center, University of
      Lausanne, Lausanne, Switzerland.
FAU - Boni, Jurg
AU  - Boni J
AD  - Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
FAU - Metzner, Karin J
AU  - Metzner KJ
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital
      Zurich, Zurich, Switzerland.
AD  - Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
FAU - Kouyos, Roger D
AU  - Kouyos RD
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital
      Zurich, Zurich, Switzerland.
AD  - Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
FAU - Gunthard, Huldrych F
AU  - Gunthard HF
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital
      Zurich, Zurich, Switzerland.
AD  - Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20190102
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases
      Society of America
JID - 9203213
EDAT- 2019/01/03 06:00
MHDA- 2019/01/03 06:00
CRDT- 2019/01/03 06:00
PHST- 2018/10/01 00:00 [received]
PHST- 2019/01/03 06:00 [entrez]
PHST- 2019/01/03 06:00 [pubmed]
PHST- 2019/01/03 06:00 [medline]
AID - 5269466 [pii]
AID - 10.1093/cid/ciy1131 [doi]
PST - aheadofprint
SO  - Clin Infect Dis. 2019 Jan 2. pii: 5269466. doi: 10.1093/cid/ciy1131.

PMID- 30601947
OWN - NLM
STAT- Publisher
LR  - 20190102
IS  - 1537-6591 (Electronic)
IS  - 1058-4838 (Linking)
DP  - 2019 Jan 2
TI  - Antiretroviral monotherapy for HIV. Game over or future perspectives?
LID - 10.1093/cid/ciy1136 [doi]
FAU - Rijnders, Bart J A
AU  - Rijnders BJA
AD  - Erasmus MC, Section of infectious Diseases, Rotterdam, the Netherlands.
FAU - Rokx, C
AU  - Rokx C
AD  - Erasmus MC, Section of infectious Diseases, Rotterdam, the Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20190102
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases
      Society of America
JID - 9203213
EDAT- 2019/01/03 06:00
MHDA- 2019/01/03 06:00
CRDT- 2019/01/03 06:00
PHST- 2018/12/18 00:00 [received]
PHST- 2019/01/03 06:00 [entrez]
PHST- 2019/01/03 06:00 [pubmed]
PHST- 2019/01/03 06:00 [medline]
AID - 5269431 [pii]
AID - 10.1093/cid/ciy1136 [doi]
PST - aheadofprint
SO  - Clin Infect Dis. 2019 Jan 2. pii: 5269431. doi: 10.1093/cid/ciy1136.

PMID- 30480732
OWN - NLM
STAT- MEDLINE
DCOM- 20181228
LR  - 20181228
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 320
IP  - 20
DP  - 2018 Nov 27
TI  - Seeing the Present Through the Past: History, Empathy, and Medical Education.
PG  - 2079-2080
LID - 10.1001/jama.2018.17253 [doi]
FAU - Koretzky, Maya Overby
AU  - Koretzky MO
AD  - Department of History of Medicine, Johns Hopkins School of Medicine, Baltimore,
      Maryland.
LA  - eng
PT  - Historical Article
PT  - Journal Article
PT  - Personal Narrative
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
SB  - AIM
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/*history
MH  - *Education, Medical
MH  - *Empathy
MH  - Female
MH  - *History of Medicine
MH  - History, 20th Century
MH  - Humans
MH  - Male
MH  - Patient Care/psychology
MH  - *Physician-Patient Relations
EDAT- 2018/11/28 06:00
MHDA- 2018/12/29 06:00
CRDT- 2018/11/28 06:00
PHST- 2018/11/28 06:00 [entrez]
PHST- 2018/11/28 06:00 [pubmed]
PHST- 2018/12/29 06:00 [medline]
AID - 2716567 [pii]
AID - 10.1001/jama.2018.17253 [doi]
PST - ppublish
SO  - JAMA. 2018 Nov 27;320(20):2079-2080. doi: 10.1001/jama.2018.17253.

PMID- 30602023
OWN - NLM
STAT- Publisher
LR  - 20190102
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
DP  - 2019 Jan 2
TI  - High resolution evolutionary analysis of within-host hepatitis C virus infection.
LID - 10.1093/infdis/jiy747 [doi]
AB  - Background: Despite the recent breakthroughs in the treatment of HCV infection,
      we have a limited understanding of how virus diversity generated within
      individuals impacts the evolution and spread of HCV variants at the population
      scale. Addressing this gap is important for identifying the main sources of
      disease transmission and for evaluating the risk of drug-resistance mutations
      emerging and disseminating in a population. Method: We have undertaken a
      high-resolution analysis of HCV within-host evolution from four individuals
      co-infected with HIV. We used long-read, deep-sequenced data of the full-length
      HCV envelope glycoprotein, longitudinally sampled from acute to chronic HCV
      infection to investigate the underlying viral population and evolutionary
      dynamics. Results: We found statistical support for population structure
      maintaining the within-host HCV genetic diversity in three out of four
      individuals. We also report the first population genetic estimate of the
      within-host recombination rate for HCV (0.28x10 -7 recombination/site/year),
      which is considerably lower than that estimated for HIV-1 and the overall
      nucleotide substitution rate estimated during HCV infection. Conclusion:
      Together, these observations indicate that population structure and strong
      genetic linkage shapes within-host HCV evolutionary dynamics. These results will 
      guide the future investigation of potential HCV drug resistance adaptation during
      infection, and at the population scale.
FAU - Raghwani, Jayna
AU  - Raghwani J
AD  - Big Data Institute, Li Ka Shing Centre for Health Information and Discovery,
      Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
FAU - Wu, Chieh-Hsi
AU  - Wu CH
AD  - Department of Statistics, University of Oxford, Oxford, United Kingdom.
FAU - Ho, Cynthia K Y
AU  - Ho CKY
AD  - Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam,
      Amsterdam, the Netherlands.
FAU - De Jong, Menno
AU  - De Jong M
AD  - Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam,
      Amsterdam, the Netherlands.
FAU - Molenkamp, Richard
AU  - Molenkamp R
AD  - Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam,
      Amsterdam, the Netherlands.
FAU - Schinkel, Janke
AU  - Schinkel J
AD  - Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam,
      Amsterdam, the Netherlands.
FAU - Pybus, Oliver G
AU  - Pybus OG
AD  - Department of Zoology, University of Oxford, Oxford, United Kingdom.
FAU - Lythgoe, Katrina A
AU  - Lythgoe KA
AD  - Big Data Institute, Li Ka Shing Centre for Health Information and Discovery,
      Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20190102
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
EDAT- 2019/01/03 06:00
MHDA- 2019/01/03 06:00
CRDT- 2019/01/03 06:00
PHST- 2018/09/18 00:00 [received]
PHST- 2019/01/03 06:00 [entrez]
PHST- 2019/01/03 06:00 [pubmed]
PHST- 2019/01/03 06:00 [medline]
AID - 5269822 [pii]
AID - 10.1093/infdis/jiy747 [doi]
PST - aheadofprint
SO  - J Infect Dis. 2019 Jan 2. pii: 5269822. doi: 10.1093/infdis/jiy747.

PMID- 30602611
OWN - NLM
STAT- Publisher
LR  - 20190103
IS  - 1098-5514 (Electronic)
IS  - 0022-538X (Linking)
DP  - 2019 Jan 2
TI  - HIV subtype and Nef-mediated immune evasion function correlate with viral
      reservoir size in early-treated individuals.
LID - JVI.01832-18 [pii]
LID - 10.1128/JVI.01832-18 [doi]
AB  - The HIV accessory protein Nef modulates key immune evasion and pathogenic
      functions and its encoding gene region exhibits high sequence diversity. Given
      the recent identification of early HIV-specific adaptive immune responses as
      novel correlates of HIV reservoir size, we hypothesized that viral factors that
      facilitate evasion of such responses - namely, Nef genetic and functional
      diversity - might also influence reservoir establishment and/or persistence. We
      isolated baseline plasma HIV RNA-derived nef clones from 30 acute/early-infected 
      individuals who participated in a clinical trial of early cART (<6 months
      following infection) and assessed each Nef clone's ability to downregulate CD4
      and HLA class I in vitro We then explored the relationships between baseline
      clinical, immunologic and virologic characteristics, and HIV reservoir size
      measured 48 weeks following initiation of suppressive cART (where reservoir size 
      was quantified in terms of proviral DNA loads as well as levels of
      replication-competent HIV in CD4(+) T-cells). Maximal within-host Nef-mediated
      downregulation of HLA, but not CD4, correlated positively with post-cART proviral
      DNA levels (Spearman's R=0.61; p=0.0004) and replication-competent reservoir
      sizes (Spearman's R=0.36; p=0.056) in univariable analyses. Furthermore,
      Nef-mediated HLA downregulation function was retained in final multivariable
      models adjusting for established clinical and immunologic correlates of reservoir
      size. Finally, HIV subtype B infected persons (N=25) harbored significantly
      larger viral reservoirs compared to non-B infected persons (2 CRF01_AE and 3
      subtype G infections). Our results highlight a potentially important role of
      viral factors - in particular HIV subtype and accessory protein function - in
      modulating viral reservoir establishment and persistence.IMPORTANCE While
      combination antiretroviral therapies (cART) have transformed HIV into a chronic
      manageable condition, they do not act upon the latent HIV reservoir and are
      therefore not curative. As HIV cure or remission should be more readily
      achievable in individuals with smaller HIV reservoirs, achieving a deeper
      understanding of clinical, immunologic and virologic determinants of reservoir
      size is critical to eradication efforts. We performed a post-hoc analysis of 30
      participants of a clinical trial of early cART who had previously been assessed
      in detail for their clinical, immunologic and reservoir size characteristics. We 
      observed that HIV subtype and autologous Nef-mediated HLA downregulation function
      correlated with viral reservoir size measured approximately one year post-cART
      initiation. Our findings highlight virologic characteristics - both genetic and
      functional - as possible novel determinants of HIV reservoir establishment and
      persistence.
CI  - Copyright (c) 2019 American Society for Microbiology.
FAU - Omondi, Fredrick H
AU  - Omondi FH
AD  - Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
FAU - Chandrarathna, Sandali
AU  - Chandrarathna S
AD  - Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
FAU - Mujib, Shariq
AU  - Mujib S
AUID- ORCID: https://orcid.org/0000-0002-6206-5622
AD  - Department of Medicine, University of Toronto, Toronto, ON, Canada.
FAU - Brumme, Chanson J
AU  - Brumme CJ
AD  - British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
FAU - Jin, Steven W
AU  - Jin SW
AD  - Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
FAU - Sudderuddin, Hanwei
AU  - Sudderuddin H
AD  - Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
FAU - Miller, Rachel
AU  - Miller R
AD  - Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
FAU - Rahimi, Asa
AU  - Rahimi A
AD  - Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
FAU - Laeyendecker, Oliver
AU  - Laeyendecker O
AD  - Laboratory of Immunoregulation, National Institute of Allergy and Infectious
      Diseases, National Institutes of Health, Bethesda, MD, USA.
AD  - Johns Hopkins University, Baltimore, MD, USA.
FAU - Bonner, Phil
AU  - Bonner P
AD  - Department of Medicine, University of Toronto, Toronto, ON, Canada.
FAU - Yue, Feng Yun
AU  - Yue FY
AD  - Department of Medicine, University of Toronto, Toronto, ON, Canada.
FAU - Benko, Erika
AU  - Benko E
AD  - Department of Medicine, University of Toronto, Toronto, ON, Canada.
FAU - Kovacs, Colin M
AU  - Kovacs CM
AD  - Department of Medicine, University of Toronto, Toronto, ON, Canada.
AD  - Maple Leaf Clinic, Toronto ON, Canada.
FAU - Brockman, Mark A
AU  - Brockman MA
AUID- ORCID: https://orcid.org/0000-0001-6432-1426
AD  - Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
AD  - British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
AD  - Department of Molecular Biology and Biochemistry, Simon Fraser University,
      Burnaby, BC, Canada.
FAU - Ostrowski, Mario
AU  - Ostrowski M
AD  - Department of Medicine, University of Toronto, Toronto, ON, Canada zbrumme@sfu.ca
      mario.ostrowski@gmail.com.
AD  - Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto,
      ON, Canada.
FAU - Brumme, Zabrina L
AU  - Brumme ZL
AUID- ORCID: https://orcid.org/0000-0002-8157-1037
AD  - Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada
      zbrumme@sfu.ca mario.ostrowski@gmail.com.
AD  - British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
LA  - eng
PT  - Journal Article
DEP - 20190102
PL  - United States
TA  - J Virol
JT  - Journal of virology
JID - 0113724
EDAT- 2019/01/04 06:00
MHDA- 2019/01/04 06:00
CRDT- 2019/01/04 06:00
PHST- 2019/01/04 06:00 [entrez]
PHST- 2019/01/04 06:00 [pubmed]
PHST- 2019/01/04 06:00 [medline]
AID - JVI.01832-18 [pii]
AID - 10.1128/JVI.01832-18 [doi]
PST - aheadofprint
SO  - J Virol. 2019 Jan 2. pii: JVI.01832-18. doi: 10.1128/JVI.01832-18.

PMID- 30601748
OWN - NLM
STAT- MEDLINE
DCOM- 20190111
LR  - 20190111
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 380
IP  - 1
DP  - 2019 Jan 3
TI  - Facing Opioids in the Shadow of the HIV Epidemic.
PG  - 1-3
LID - 10.1056/NEJMp1813836 [doi]
FAU - Parker, Caroline M
AU  - Parker CM
AD  - From the Departments of Sociomedical Sciences (C.M.P., J.S.H.) and Epidemiology
      (C.B., S.M.), Mailman School of Public Health, Columbia University, and the
      Department of Psychiatry, School of Medicine, New York University (H.B.H.) - both
      in New York.
FAU - Hirsch, Jennifer S
AU  - Hirsch JS
AD  - From the Departments of Sociomedical Sciences (C.M.P., J.S.H.) and Epidemiology
      (C.B., S.M.), Mailman School of Public Health, Columbia University, and the
      Department of Psychiatry, School of Medicine, New York University (H.B.H.) - both
      in New York.
FAU - Hansen, Helena B
AU  - Hansen HB
AD  - From the Departments of Sociomedical Sciences (C.M.P., J.S.H.) and Epidemiology
      (C.B., S.M.), Mailman School of Public Health, Columbia University, and the
      Department of Psychiatry, School of Medicine, New York University (H.B.H.) - both
      in New York.
FAU - Branas, Charles
AU  - Branas C
AD  - From the Departments of Sociomedical Sciences (C.M.P., J.S.H.) and Epidemiology
      (C.B., S.M.), Mailman School of Public Health, Columbia University, and the
      Department of Psychiatry, School of Medicine, New York University (H.B.H.) - both
      in New York.
FAU - Martins, Sylvia
AU  - Martins S
AD  - From the Departments of Sociomedical Sciences (C.M.P., J.S.H.) and Epidemiology
      (C.B., S.M.), Mailman School of Public Health, Columbia University, and the
      Department of Psychiatry, School of Medicine, New York University (H.B.H.) - both
      in New York.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Analgesics, Opioid)
SB  - AIM
SB  - IM
MH  - Analgesics, Opioid
MH  - *Epidemics
MH  - HIV Infections/*drug therapy/epidemiology
MH  - Humans
MH  - *Medication Adherence
MH  - Opioid-Related Disorders/*drug therapy/epidemiology
MH  - Stereotyping
MH  - United States/epidemiology
EDAT- 2019/01/03 06:00
MHDA- 2019/01/12 06:00
CRDT- 2019/01/03 06:00
PHST- 2019/01/03 06:00 [entrez]
PHST- 2019/01/03 06:00 [pubmed]
PHST- 2019/01/12 06:00 [medline]
AID - 10.1056/NEJMp1813836 [doi]
PST - ppublish
SO  - N Engl J Med. 2019 Jan 3;380(1):1-3. doi: 10.1056/NEJMp1813836.

PMID- 30601728
OWN - NLM
STAT- MEDLINE
DCOM- 20190111
LR  - 20190111
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 380
IP  - 1
DP  - 2019 Jan 3
TI  - Erythrodermic Psoriasis and HIV Infection.
PG  - 80
LID - 10.1056/NEJMicm1810005 [doi]
FAU - Bowles, Alexandra A
AU  - Bowles AA
AD  - Ohio University, Athens, OH bowlesar@gmail.com.
FAU - Smirnov, Brittany
AU  - Smirnov B
AD  - Dermatology Associates of Palm Beach, Delray Beach, FL.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Anti-Inflammatory Agents)
RN  - 1ZK20VI6TY (Triamcinolone)
SB  - AIM
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Antiretroviral Therapy, Highly Active
MH  - Biopsy
MH  - Dermatitis, Exfoliative/diagnosis/drug therapy/*etiology
MH  - HIV Infections/*complications/drug therapy
MH  - Humans
MH  - Male
MH  - Psoriasis/*complications
MH  - Triamcinolone/therapeutic use
EDAT- 2019/01/03 06:00
MHDA- 2019/01/12 06:00
CRDT- 2019/01/03 06:00
PHST- 2019/01/03 06:00 [entrez]
PHST- 2019/01/03 06:00 [pubmed]
PHST- 2019/01/12 06:00 [medline]
AID - 10.1056/NEJMicm1810005 [doi]
PST - ppublish
SO  - N Engl J Med. 2019 Jan 3;380(1):80. doi: 10.1056/NEJMicm1810005.